Skip to main content

menu
menu
person
Search

Specialty Program

Pain Management

Glycemic Regulation

PCSK9s in Interventional Cardiology

PCSK9s in Medical Preventative

PCSK9s in Lipid Medicine & Atherosclerosis Prevention

PCSK9s in Diabetes Management

PCSK9s: A Multi-Specialty Perspective

Specialty Program

Glycemic Regulation

PCSK9s in Diabetes Management

Specialty Program

Specialty Program

Parkinson's Disease

Specialty Program

Extracorporeal Photopheresis (ECP)

Pain Management

Specialty Program

Atopic Dermatitis

Pain Management

Parkinson's Disease

Glycemic Regulation

Specialty Program

Atopic Dermatitis

Extracorporeal Photopheresis (ECP)

Specialty Program

Atopic Dermatitis

Biosimilars for RA

PCSK9s in Interventional Cardiology

PCSK9s in Medical Preventative

PCSK9s in Lipid Medicine & Atherosclerosis Prevention

PCSK9s in Diabetes Management

PCSK9s: A Multi-Specialty Perspective

MAC Lung Disease

Specialty Program

MAC Lung Disease

close

person

Home
Access All Programs
Specialties
- Topics
- Biologics
- Cancer
- Cardiology
- Dermatology
- Diabetes
- Hypothyroidism
- MAC Lung Disease
- Neurology
- Primary Care
Submit A Question

Ian Odell, MD, PhD

Ian Odell, MD, PhD

Ian Odell, MD, PhD

Assistant Professor

Dermatology Director, Adult Primary Care Center

Scleroderma and Myositis Program

Yale University School of Medicine

Can you provide a brief review of scleroderma—systemic sclerosis—as a multisystem connective tissue disease characterized by humoral and cellular immune abnormalities and fibroblast activation?

Can you provide a brief review of scleroderma—systemic sclerosis—as a multisystem connective tissue disease characterized by humoral and cellular immune abnormalities and fibroblast activation?

Ian Odell, MD, PhD

Given the multiple clinical phenotypes and subtypes that are observed with systemic sclerosis, what therapeutic approaches are aligned with what forms of the disease? And what is the evidence-based role for ECP?

Given the multiple clinical phenotypes and subtypes that are observed with systemic sclerosis, what therapeutic approaches are aligned with what forms of the disease? And what is the evidence-based role for ECP?

Ian Odell, MD, PhD

What findings of progressive skin involvement with scleroderma are clinical triggers to warrant consideration of ECP in the heterogeneous population of patients? What is the clinical trial data supporting the use of ECP in scleroderma?

What findings of progressive skin involvement with scleroderma are clinical triggers to warrant consideration of ECP in the heterogeneous population of patients? What is the clinical trial data supporting the use of ECP in scleroderma?

Ian Odell, MD, PhD

Based on clinical trial data, the benefit-to-risk equation, contraindications, and experience with ECP at your institution, which patients with scleroderma are you treating with ECP, and what strategies are you deploying to optimize outcomes?

Based on clinical trial data, the benefit-to-risk equation, contraindications, and experience with ECP at your institution, which patients with scleroderma are you treating with ECP, and what strategies are you deploying to optimize outcomes?

Ian Odell, MD, PhD

What is the schedule—i.e. frequency of ECP treatments—that patients with scleroderma require, and what are the possible side effects that require monitoring?

What is the schedule—i.e. frequency of ECP treatments—that patients with scleroderma require, and what are the possible side effects that require monitoring?

Ian Odell, MD, PhD

Since you and others at Yale have treated a number of patients with scleroderma—and other conditions—with ECP, can you share your real world clinical experience with this treatment modality? And how measure clinical response to this therapy?

Since you and others at Yale have treated a number of patients with scleroderma—and other conditions—with ECP, can you share your real world clinical experience with this treatment modality? And how measure clinical response to this therapy?

Ian Odell, MD, PhD

Disclaimer:
Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Clinical Webcasts®

Powered by BROADCASTMED